Johnson P J, McFarlane I G, McFarlane B M, Williams R
Liver Unit, King's College Hospital, Denmark Hill, London, UK.
J Gastroenterol Hepatol. 1990 May-Jun;5(3):244-51. doi: 10.1111/j.1440-1746.1990.tb01624.x.
In patients with chronic active hepatitis (CAH), the absence of the conventional serum auto-antibodies (antinuclear, smooth muscle and liver-kidney microsomal) is often taken as evidence against an auto-immune aetiology and as indicative that the disease is unlikely to respond to immunosuppressive therapy. We report 12 British patients (11 female) who presented with histologically florid CAH (11 with cirrhosis or fibrosis and seven with ascites) but without significant titres of these antibodies or any other demonstrable aetiological feature (cryptogenic CAH), who have been followed up for a median of 5.25 years (range: 0.75-16 years). Ten had hypergammaglobulinaemia and/or specific elevations of serum IgG concentrations at presentation and five of 10 patients tested were found to have the HLA allotypes B8 and DR3. Remission was initially induced with prednisolone with or without azathioprine in all patients. Six patients subsequently relapsed on one or more occasions, either spontaneously while on maintenance therapy or during attempts to withdraw corticosteroids, and required increases or reintroduction of immunosuppressive therapy to regain disease control. Retrospective analysis of pretreatment samples from 11 of the patients revealed that all had been seropositive at presentation for auto-antibodies against the liver membrane lipoprotein preparation known as liver-specific membrane lipoprotein (LSP) and/or against the hepatic asialoglycoprotein receptor (ASGP-R), titres of which subsequently fluctuated in direct relation to response to treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
在慢性活动性肝炎(CAH)患者中,传统血清自身抗体(抗核抗体、平滑肌抗体和肝肾微粒体抗体)的缺乏常被视为排除自身免疫病因的证据,表明该疾病不太可能对免疫抑制治疗有反应。我们报告了12例英国患者(11例女性),他们表现为组织学上明显的CAH(11例有肝硬化或纤维化,7例有腹水),但这些抗体滴度不高,也没有任何其他可证实的病因特征(隐源性CAH),随访时间中位数为5.25年(范围:0.75 - 16年)。10例患者在就诊时有高球蛋白血症和/或血清IgG浓度特异性升高,10例接受检测的患者中有5例具有HLA同种异型B8和DR3。所有患者最初均使用泼尼松龙联合或不联合硫唑嘌呤诱导缓解。6例患者随后复发一次或多次,要么在维持治疗期间自发复发,要么在试图停用皮质类固醇期间复发,需要增加或重新引入免疫抑制治疗以重新控制疾病。对11例患者治疗前样本的回顾性分析显示,所有患者在就诊时针对称为肝特异性膜脂蛋白(LSP)的肝膜脂蛋白制剂和/或针对肝去唾液酸糖蛋白受体(ASGP - R)的自身抗体均为血清阳性,其滴度随后与治疗反应直接相关波动。(摘要截断于250字)